Questions & Answers
- Medicinal products
- Human and veterinary -
(labelling and package leaflet)

This document only covers questions for products authorised in the national, MR and DC procedures. The answers given below are valid for Denmark (DK), Finland (FI), Iceland (IS), Norway (NO) and Sweden (SE) unless otherwise specified.

General questions concerning labelling

1. Is there something specific an applicant should consider before submission of an application if the applicant plans a Nordic package, i.e. a package for two or more Nordic countries.

Before submission of any application the applicant should carefully consider the labelling which is actually required according to labelling guidelines provided in the annotated QRD and QRDvet templates. It is recommended that the applicant only proposes labelling which is considered to be necessary.

Before submission the applicant should also consider all available options for the mock-up regarding harmonised translation, e.g. the use of abbreviated Latin terms for the active substance and excipients, the use of the abbreviations “Lot” and “EXP”, the use of abbreviations like “i.m.”, “i.v.” and “s.c.”, etc. For writing the active substance in Latin, please see the specific question below about Latin language.

Before submission the applicant is strongly recommended to create a mock-up of the Nordic package (blister, foil, strip, label, carton) to ensure that a Nordic package will be feasible based on the proposed labelling.

2. Is it possible to achieve a Nordic package for a product, if the marketing authorisations have already been granted via the national procedure in the relevant Nordic countries? How should the marketing authorisation holder proceed in case of differences in the product information?

Yes, it is possible to achieve a Nordic package although the product has been approved via a national procedure in each country.

However, a common Nordic package cannot be achieved unless the following is fulfilled;

- The name and the strength of the medicinal product must be the same
- The SmPC/SPC, package leaflet and labelling (product information) must be identical
- The legal status (POM/OTC) must be the same

Furthermore, the multilingual package is only possible if the readability is not compromised by adding 2 or more languages to the labelling elements.

If your product needs to be harmonised before a common Nordic package can be achieved, then this should be done in accordance with Commission Regulation (EC) No 1234/2008 as amended concerning variations and standard fee is required. If the outcome of the variation is to achieve common Nordic packages, a work sharing variation should be considered to achieve common harmonised English SmPC/SPC, package leaflet and labelling.
Guideline on Nordic packages

Applicants are encouraged to use the Nordic mock-up cooperation - see under “Related information”
Please notice that DK does not participate in this cooperation.

3. Could Nordic Packages be accepted for parallel imported medicinal products?

Nordic packages could be accepted for parallel imported products provided that the requirements for Nordic Packages are fulfilled. A common Nordic package cannot be achieved unless the following is fulfilled:

- The name and the strength of the medicinal product must be the same
- The SmPC/SPC, package leaflet and labelling (product information) must be identical
- The legal status (POM/OTC) must be the same
- The labelling is submitted for approval nationally in each country
- The national requirements for the labelling of the parallel imported products should be fulfilled.

Furthermore, the parallel importer should ensure that the GMP term “homogen batch” is complied with for the Nordic Package. This would e.g. mean that the same product (MA no) from the same exporting country is approved in the Nordic countries. The parallel imported product also needs to have the same shelf life and storage conditions approved in the Nordic countries. The parallel importer needs to consider carefully if the package leaflets for the parallel imported product are identical in the Nordic countries as this is a prerequisite for having Nordic Packages.

4. Should mock-ups for a Nordic package be approved in the respective Nordic medicines agencies for MR and DC procedures?

FI, NO, SE: Mock-ups should be approved by the concerned national medicines agencies.

IS: Mock-ups must be submitted. However, the Icelandic Medicines Agency does normally not assess/review the mock-ups except when participating in the Nordic mock-up cooperation. It is considered to be the responsibility of the marketing authorisation holder to ensure correct labelling, legibility, appropriate layout etc.

DK: Mock-ups are not assessed or approved by DKMA. Regularly DKMA carries out random compliance checks of product labelling. The labelling text should contain the same information in all languages.

5. If an applicant plans a Nordic package and it is foreseen that for example Latin terms will be used for the active substance(s) and excipients, as well as abbreviations like “EXP” and “Lot”, should the labelling translation in word format correspond to the mock-ups?

FI, IS, NO, SE: The labelling translation in the word format should be a strict translation of the final English labelling text. Latin and exemptions are only included in the mock-ups.

DK: DK do not assess the mock up, therefore the text in the word format should reflect the mock-up.

6. Are there any national requirements for the minimum font size?

The minimum requirements given in the Readability Guideline for human medicinal products should be used for common Nordic packages (human and veterinary). The font style should also be considered.
7. What are the requirements if a company wants to add a QR-code/URL?

Questions regarding QR-codes are out of scope for the Nordic package group. However, we present the following information:

For human products authorised in DCP, MRP or NP reference is made to the information (position paper) published on the CMDh web site:


For veterinary products reference is made to the information published on the EMA website:


For questions regarding CP products EMA must be contacted. See EMA web site for guidance.

8. Can a sticker with national labelling be used to fulfil national labelling requirements or be used to hide information?

For DK, IS, NO and SE this is a possible way to add information as an exemption, as long as readability is not compromised and the labelling is in accordance with the approved text and national requirements. This is common practice in Iceland but marketing authorisation holders are strongly encouraged to update their products to include Icelandic labelling. The sticker must be permanent and the addition of a sticker must be done by a manufacturer with a valid license.

FI: A sticker may be used to add the red warning triangle on the labelling but not for any other purposes. Stickers are not accepted to over-label or hide information on the labelling. The sticker must be permanent and the addition of a sticker must be done by a manufacturer with a valid license.

SE: In cases when the red warning triangle is required in DK, NO and/or FI the triangle may be hidden by a sticker on the packages intended for SE. If the sticker is added after batch release a specific permission to do this is required from the MPA.

Please see also Commission Q&A on safety features for additional information on the use of stickers for addition of the unique identifier.

9. Are the EMA QRD and QRD vet templates accepted for national products?

Yes.

10. How should “EXP” and “Lot” be placed on unit-dose blisters?

All information required for blisters must appear on each unit dose presentation. For statement of “Lot” and “EXP”, the following applies:
Guideline on Nordic packages

For a unit-dose blister is it acceptable only to state “Lot” and “EXP” once at the end or at the side?
DK, IS: Yes
FI, NO, SE: If registered and approved as a unit dose blister: No, “Lot” and “EXP” should be stated on each unit of the blister.

If not registered and approved as a unit dose blister i.e. the blister is considered to be just a perforated blister: Yes, “Lot” and “EXP” do only have to be stated once on the blister.

11. What kind of logos are accepted on packages in the Nordic countries?
Last update: 2018-04-23

Only logo of the MAH and the local representative (if applicable) in accordance with the application form can be accepted.
The readability must not be negatively affected, nor must such a logo take up space from the required information, e.g. product logos and company logos should be avoided if they prevent multilingual packages. Logos must not be of a promotional nature.

It is not a requirement or necessary to have company logos on the package.

12. Must the local representative be stated on the package?
Last update: 2018-04-23

No. As space restrictions are common it is recommended not to print this information on the package, as it will be mentioned in the leaflet.

13. Is it acceptable to state the local distributor (wholesaler) on the package?
Last update: 2014-01-30

No.

14. How should the calendar days be stated on a calendar blister?
Last update: 2018-04-23

Either the name of the day or an abbreviation should be used. Please, refer to the European Medicine Agency’s QRD reference documents and guidance.

<table>
<thead>
<tr>
<th></th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
<th>Sunday</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark</td>
<td>Man</td>
<td>Tirs</td>
<td>Ons</td>
<td>Tors</td>
<td>Fre</td>
<td>Lør</td>
<td>Søn</td>
</tr>
<tr>
<td>Finland</td>
<td>Ma</td>
<td>Ti</td>
<td>Ke</td>
<td>To</td>
<td>Pe</td>
<td>La</td>
<td>Su</td>
</tr>
<tr>
<td>Iceland</td>
<td>Má</td>
<td>Þrí</td>
<td>Mi</td>
<td>Fi</td>
<td>Fö</td>
<td>Lau</td>
<td>Su</td>
</tr>
<tr>
<td>Sweden</td>
<td>Mån</td>
<td>Tis</td>
<td>Ons</td>
<td>Tors</td>
<td>Fre</td>
<td>Lør</td>
<td>Sön</td>
</tr>
</tbody>
</table>
Guideline on Nordic packages

On a case by case basis, further abbreviations could be discussed and accepted by the authorities.

DK: In the national guidance “Vejledning til bekendtgørelse om mærkning m.m.” a list of different abbreviations for calendar days is included.

15. **How soon, following approval of non-urgent changes in the labelling and package leaflet, must the changes be implemented?**

A general rule is that changes would be expected to be implemented for the next batch manufactured of the product. However, at present different timelines apply in the Nordic countries:

NO: Any batch QP released 6 months or more after an approval must consist of the updated labelling and/or package leaflet.
SE: Production of new packages including the changes should be started within 6 months after approval.
DK: The changes should be implemented within 6 months after approval. However if it is stated in the current package leaflet that the newest version is uploaded on the Danish Medicines Agency’s web page the implementation time is 12 months.
FI, IS: The implementation should be made for the next possible batch.

On a case by case basis, depending on the urgency of the changes, authorities may request implementation earlier than the timelines mentioned above.

16. **Can the Nordic agencies provide an example of a Nordic package and are there some practical advices which should be kept in mind?**

See Annex I: “Dummy” mock-ups is for information purpose only.

**Name of the product**

17. **Can the applicant ask the medicines agencies in DK, FI, IS, NO and SE to assess and approve a name of a product before submission of an application?**

No.

The name of a product is assessed during a marketing authorisation application/variation procedure and any name issues should if possible be solved before end of procedure.

It is important that an applicant who is planning a Nordic package inform the Nordic agencies of this when proposing a name for a product. The Nordic agencies will then have the opportunity to communicate, if necessary, in order to approve the same name for all five Nordic countries.

DK: It is not possible to reserve a product name in DK. A final evaluation of the name will always be made before final approval of the MA.
18. For a product which is given a generic product name, can the INN be written in English?

Yes, unless the English term is very different from the national one, for example if the name includes “potassium” or “sodium”.

19. For a product which is given the generic name of the active substance, which is for example a salt, should the salt be a part of the name?

SE: No, the salt should normally not be part of the name. Inclusion complicates the name, makes it longer and harder to remember for a patient.

DK, IS: If the strength is given in relation to the salt then the salt should be part of the name. However, for common Nordic packages it is possible to be more flexible and deviate from this practice, if no safety issues are related.

FI, NO: No, the salt should not be part of the name unless the salt has an impact on the effect of the medicinal product. However, as there are products on the market with salt as part of the generic name, the generic name with the salt will also continue to be required for any new medicinal products containing the same substance.

20. When printing the name of the active substance(s) on the package, in connection with the name of the product, should the name of the active substance(s) begin with an upper or lower case letter?

The name of the active substance(s) should in these cases begin with a lower case letter, to clearly separate the name of the active substance(s) from the name of the product.

21. Should the name of the active substance(s) be printed below the name of the product, even if the name of the product is the INN + company name?

In cases when the strength does not correspond to the active moiety:
Yes.
In cases when the strength correspond to the active moiety:
SE: Yes. Always required for the outer package. On blisters and small immediate packages the active substance can be left out if space problems occur if the name of the product is a generic name.

DK, FI, IS, NO: No.

22. Is it allowed to print the name of the product in capital letters?

It is strongly recommended that the name of a product is not printed in capital letters, except for the first letter in the name.

23. Is it acceptable to print the suffix in a name, in another colour than the name itself?

No, normally not acceptable.
Guideline on Nordic packages

24. Which suffixes are acceptable as a part of the invented name of a product?
Last update: 2018-04-23

In the past suffixes were sometimes considered necessary to separate strengths and/or pharmaceutical forms. Today, suffixes should normally be avoided and are generally discouraged as the strength and pharmaceutical form would be clearly stated on the package. This is especially relevant for Nordic packages, however see one exception below. Suffixes that are promotional are not accepted.

Not all suffixes are acceptable in all Nordic countries. Hence, carefully consider the need for a suffix if the goal is to have a Nordic package.

FI, NO, SE: The suffix “Vet” is recommended for all veterinary products.

DK, IS: The suffix “Vet” is accepted for all veterinary products.

Strength

25. Must the strength be stated in the same font size and font style as the name of the product?
Last update: 2014-01-30

Yes, strongly recommended whenever possible.

26. If the strength of a product is given in micrograms, can the abbreviations “mcg” or μg be used?
Last update: 2018-04-23

No. The appropriate abbreviated term in each language should be used, i.e.:

DK, FI, NO, SE: mikrog

IS: mikróg (exceptionally, the term “mikrog” can be used) for Nordic packages.

It should be noted that if the abbreviation is identical for two or more countries, it should not be repeated on the package.

27. Is it acceptable to state the strength of a product as “%” or “ppm”?
Last update: 2014-01-30

As a general rule “%” and “ppm”, as well as other similar units shall be avoided and the strength should be stated as for example mg/ml, mg/g etc. The strength cannot be stated in two different ways on the package, i.e. both as for example mg/ml and %.

28. When the strength of a product is stated in International Units, i.e. “IU” is it then acceptable to use “IU” on the Nordic packages, instead of the abbreviations “IE” (DK, NO, SE), “KY” (FI) and “a.e.” (IS)?
Last update: 2014-01-30

Yes. Please note that when the abbreviation “IU” is used, it should be the only abbreviation for International Units on the Nordic package, i.e. do not mix “IU” with the national abbreviations.
29. When the strength of a product is stated in Units, i.e. “U” is it then acceptable to use “U” on the Nordic packages? As regards International Units, please see the question about IU.

Last update: 2015-02-25

FI, IS, NO: Yes. “U” can be used, but if the package is shared with DK/SE who do not allow the abbreviation the units must be stated in the same way for all languages i.e. full term.
DK, SE: No. “Units” should not be abbreviated. The appropriate translations should be used:

DK: enheder
FI: yksikköä
IS: einingar
NO, SE: enheter

30. Is it acceptable to print the strength in different colours for products available in more than one strength to avoid mix-up?

Last update: 2014-01-30

Yes, packages for different strengths should be distinguished from each other. It is strongly recommended to use different colours for different strengths.

Pharmaceutical form

31. If the pharmaceutical form consists of two or more words, for example “film-coated tablet” must all the words be printed in one line?

Last update: 2018-04-23

It is strongly recommended to print the full pharmaceutical form in one line. When relevant and if possible each language should be in separate lines.

32. Which pharmaceutical forms can be abbreviated on the outer package, label, blister, etc.?

Last update: 2018-04-23

The full standard term must appear on the outer package at least once, and in connection with the name of the product, on the most prominent area of the package, e.g. the front panel on a carton. EDQM patient friendly short terms can be used for other locations on the carton and immediate packaging material, if necessary.

Further abbreviations are possible and can replace the patient friendly terms in cases when space is very limited. When combining the abbreviations they should be separated by a “/” and when the abbreviation is identical in two or more countries it shall only be printed once.
Guideline on Nordic packages

Following is a list of abbreviations which are acceptable

<table>
<thead>
<tr>
<th>Pharmaceutical form</th>
<th>DK Singular / Plural</th>
<th>FI Singular / Plural</th>
<th>IS Singular / Plural</th>
<th>NO Singular / Plural</th>
<th>SE Singular / Plural</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsule</td>
<td>kaps.</td>
<td>kaps.</td>
<td>hyliki / hyliki</td>
<td>kaps.</td>
<td>kaps.</td>
</tr>
<tr>
<td>Chewable tablet</td>
<td>tyggetabl.</td>
<td>purutabl.</td>
<td>tuggut. / tuggut.</td>
<td>tyggetabl.</td>
<td>tuggtabl.</td>
</tr>
<tr>
<td>Emulsion for injection</td>
<td>inj.</td>
<td>inj.</td>
<td>stl. / stl.</td>
<td>inj.væske/inj.</td>
<td>inj.</td>
</tr>
<tr>
<td>Eye drops</td>
<td>-</td>
<td>-</td>
<td>augndr. / augndr.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Film-coated tablet</td>
<td>tabl.</td>
<td>tabl.</td>
<td>tafla / töflur</td>
<td>tabl.</td>
<td>tabl.</td>
</tr>
<tr>
<td>Gastro-resistant capsule</td>
<td>enterokaps.</td>
<td>enterokaps.</td>
<td>magasýruþ. hyliki. / magarsýruþ. hyliki</td>
<td>enterokaps.</td>
<td>enterokaps.</td>
</tr>
<tr>
<td>Gastro-resistant tablet</td>
<td>enterotabl.</td>
<td>enterotabl.</td>
<td>magasýruþ. tafla / magasýruþ. töflur</td>
<td>enterotabl.</td>
<td>enterotabl.</td>
</tr>
<tr>
<td>Orodispensible tablet</td>
<td>suussa hajoava tabl.</td>
<td>munndr.tafla / munndr.töflur</td>
<td>smeltetabl.</td>
<td>munsönderfallande tabl.</td>
<td></td>
</tr>
<tr>
<td>Prolonged-release capsule</td>
<td>depotkaps.</td>
<td>depotkaps.</td>
<td>-</td>
<td>depotkaps.</td>
<td>depotkaps.</td>
</tr>
<tr>
<td>Prolonged-release tablet</td>
<td>depottabl.</td>
<td>depottabl.</td>
<td>-</td>
<td>depottabl.</td>
<td>depottabl.</td>
</tr>
<tr>
<td>Solution for infusion</td>
<td>inf.</td>
<td>-</td>
<td>innr.lyf / innr.lyf</td>
<td>inf.væske</td>
<td>-</td>
</tr>
<tr>
<td>Solution for injection</td>
<td>inj.</td>
<td>inj.</td>
<td>stl. / stl.</td>
<td>inj.væske/inj.</td>
<td>inj.</td>
</tr>
<tr>
<td>Sublingual tablet</td>
<td>resoriblet, subling.</td>
<td>resoriblet.</td>
<td>tungurötartafia/tungurötartöflur</td>
<td>Sublingvaltabl.</td>
<td>resoriblett</td>
</tr>
<tr>
<td>Suppository</td>
<td>supp.</td>
<td>endab.still / endab.stilar</td>
<td>stikkp.</td>
<td>supp.</td>
<td></td>
</tr>
<tr>
<td>Suspension for injection</td>
<td>inj.</td>
<td>inj.</td>
<td>stl. / stl.</td>
<td>inj.væske/inj.</td>
<td>inj.</td>
</tr>
<tr>
<td>Tablets</td>
<td>tabl.</td>
<td>tabl.</td>
<td>tafla / töflur</td>
<td>tabl.</td>
<td>tabl.</td>
</tr>
</tbody>
</table>

Regarding sublingual tablet: Additionally, the following possibility has been agreed and can be used as an extra option for a common label of a blister in the mentioned countries: DK/FI/SE: “resoribletit/resoribletter”

33. For capsules and tablets, is it acceptable if the pharmaceutical form is depicted on the outer package?  
Last update: 2018-04-23

Yes, if the pictogram is in life size and reflects the shape and score line, if any.

The active substance and excipients

34. Can the active substance(s) and excipients be written in Latin on a Nordic package?  
Last update: 2014-01-30

Yes.

35. Is it acceptable to use an abbreviation of the Latin term for the active substance(s) and excipients on a Nordic package and if so, how should these abbreviations be?  
Last update: 2015-02-25

Yes.

These abbreviations are accepted and encouraged to facilitate the Nordic package. When relevant the labelling sections for active substance(s) and excipient(s) can be combined on the package, using abbreviations of the Latin terms, e.g.:

“1 ml: metoprolol. tartr. resp. metoprolol. 1 mg, natr. chlorid., aq. ad iniect.”
Guidelines on Nordic packages

"1 ml: butorphanol. tartr. resp. butorphanol. 15 mg, chlorocresol., natr. chlorid., aq. ad iniet.”

Guidelines on abbreviations of the Latin name for active substances and excipients.

1) If the Latin name ends with -um, -us, -ium, -eum, these endings should be replaced with a full stop.  
Example: 
coffeinum → coffein.

2) If the Latin name ends with -icum (-ici), -oicum (-oici), -ucum (-uici), these endings should be replaced with a full stop.  
Example: 
aceticum → acet.

3) The endings -as, -oas, -ias, -eas should be replaced with a full stop.  
Example: 
citras → citr.

4) The endings -i and -ii should be replaced with a full stop.  
Example: 
calcii → calc.

5) Nominative and genitive cases have the same abbreviation. 
Example: 
natrium → natr.  
natrii → natr.

Exemptions: 
aluminium → alum.  
aqua → aq.  
argentum → arg.  
bismuthum → bism.  
carbonas → carb.  
hydrargyrum → hydrarg.  
magnesium → magn.  
salicylas → salic.

Other abbreviations - excipients: 
water for injections → aq. ad iniet.  
purified water → aq. purif.

36. Is there a way to shorten the translation of “Each tablet contains xx mg <active substance>”, “Each capsule contains xx mg <active substance>”?  
Last update: 2014-01-30

Yes. In many cases it would be possible to abbreviate this sentence. For example “1 tabl./tafla: xx mg <active substance (in Latin)>”, “1 kaps./hylki: xx mg <active substance (in Latin)>”, “1 ml: xx mg <active substance (in Latin)>”. This abbreviated text covers all five Nordic countries.

It should be noted that if excipients are to be stated on the package, they could follow the active substance, e.g. “1 kaps./hylki: xx mg <active substance (in Latin)>, lactos.”
Pharmaceutical form and contents

37. Must the number of e.g. tablets and capsules be stated in the same row as the pharmaceutical form?

Last update: 2014-01-30

No.

Routes of administration

38. Can the parenteral routes of administration be abbreviated?

Last update: 2015-02-25

The following abbreviations are accepted by all Nordic authorities for small immediate packaging:
For intramuscular use: i.m.
For intravenous use: i.v.
For subcutaneous use: s.c.
Other routes must be stated in their full form.

DK, IS, SE: The above mentioned abbreviations are also accepted for the outer packaging.

39. Is it acceptable not to print the sentence “For oral use” on the package for all formulations of tablets and capsules which are to be swallowed?

Last update: 2018-04-23

Yes. It is acceptable to leave out “For oral use” on the package. Please note that in these cases the text must be left out on the package for all countries which share the package.

NO, SE: For veterinary products, the route of administration should be stated, also “for oral use”.

If DK, FI and/or IS are combined with NO and/or SE the route of administration must also be stated in the corresponding language(s).

40. Is it acceptable not to print the sentence “For ocular use” on the package for pharmaceutical forms which are clearly stated as eye drops or eye ointment?

Last update: 2014-01-30

In case of space restrictions for such products, which are often small packages, a case by case decision to leave out the route of administration can be considered for a Nordic package.

Special warnings

41. Should cytostatic products be labelled “Cytostaticum” on the outer package, or immediate package, if there is no outer package?

Last update: 2014-01-30

Yes, this is a requirement for cytotoxic/cytostatic medicinal products.

Expiry date
42. Is it acceptable to use the abbreviation “EXP” on the outer/immediate packaging material?

Yes.

43. Is it enough only to print the actual expiry date and leave out the abbreviation “EXP”?

Yes, for small immediate packaging and blisters.

**Storage conditions**

44. Must storage conditions always be printed on the package, for example “Do not store above 25°C” and “Do not store above 30°C”?

Yes. The only exemption is “No special storage conditions”, in which case nothing regarding storage conditions should be printed on the package.

DK, IS: For purely nationally authorised products “Do not store above 30 °C” can be left out on the package.

**Name and address of the marketing authorisation holder**

45. As regards the address of the marketing authorisation holder which is to be printed on the outer/immediate package must the country be mentioned and does it have to appear in each language covered by the package?

Yes, the country must be mentioned in the different languages.

46. Is it acceptable to print the marketing authorisation holder’s phone number and e-mail address on the package?

Yes. The contact information to the marketing authorisation holder is however mentioned in the package leaflet. If there are space restrictions due to the extent of the labelling text/size of the package it is not recommended to print such information on the package.

47. Is it possible to have common Nordic packages for products with different marketing authorisation holders (which are legally independent companies with the same owner)?

If the names for the marketing authorisation holder are clearly different it is not possible to have a common package. However, if the names of the marketing authorisation holder are very similar, e.g. “XXXXXX AS”, “XXXXXX OY”, “XXXXXX AB” a common package could be possible.
48. What is the format of the marketing authorisation numbers in the Nordic countries?

Last update: 2018-04-23

The format is as follows:

<table>
<thead>
<tr>
<th>Marketing Authorisations*)</th>
<th>Parallel Import</th>
<th>Traditional Herbal Medicinal Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>DK</td>
<td>MTnr xxxx (DK)</td>
<td>MTnr xxxx (DK)</td>
</tr>
<tr>
<td>FI</td>
<td>MTnr xxxx (FI)</td>
<td>MTnr xxxx (FI)</td>
</tr>
<tr>
<td>IS</td>
<td>MTnr xxxxx (IS) or IS/x/xx/xx/xx</td>
<td>IS/x/xx/xx/xx/SA</td>
</tr>
<tr>
<td>NO</td>
<td>MTnr xx-xxxxx (NO)</td>
<td>MT(PI)nr xx-xxxxx (NO)</td>
</tr>
<tr>
<td>SE</td>
<td>MTnr xxxx (SE)</td>
<td>MTnr xxxx (SE)</td>
</tr>
</tbody>
</table>

*) The country abbreviation, „(XX)“ should be used on packages which are shared with two or more countries but it is not required for single country packages.

When printing the marketing authorisation numbers on the package they can be arranged in such a way that “MTnr” only needs to be printed once. For example the numbers can be printed in a line or in a column. Examples:

a) MTnr: xxxx (DK), xxxx (FI), xx-xxxxx (NO), xxxx (SE), IS/x/xx/xx/xx

b) MTnr xxxx (DK)

xxxx (FI)
xx-xxxx (NO)
xxxx (SE)
IS/x/x/xx/xx (IS)

Batch number

49. Is it acceptable to use the abbreviation “Lot” for the batch number on the outer and immediate packaging material?

Last update: 2014-01-30

Yes.

50. Must the abbreviation “Lot” be printed on blisters or is it enough to only print the actual batch number?
It is preferred to print “Lot” in logical connection to the actual batch number, but if that is not possible, it is acceptable to print only the actual batch number, i.e. without the abbreviation “Lot.”

**Vnr (Nordic Article Number)**

51. Where can information regarding Vnrs be found?

Questions regarding Nordic Article Numbers are out of scope for the Nordic Package Group. Information and guidelines regarding Vnrs can be found via [http://wiki.vnr.fi/](http://wiki.vnr.fi/)

**General classification of supply**

52. Is it acceptable not to print on the package the text “Medicinal product subject to medical prescription” and “Medicinal product not subject to medical prescription” (in national languages)?

Yes, for human products it is acceptable to leave out the text “Medicinal product subject to medical prescription.” None of the Nordic countries require this information. The sentence can be left out on the mock-up even if it is stated in the word format approved labelling text.

SE: For packages with OTC status it is a strongly recommended to have the text “Medicinal product not subject to medical prescription” (in national language).

For veterinary products it is a legal requirement to add “To be supplied only on veterinary prescription” in national languages on the package.

53. Can a potential applicant ask the medicines agencies in DK, FI, IS, NO and SE to confirm, before submission of an application, if a product will be granted an OTC status?

No. A possible OTC status will be assessed during the marketing authorisation application procedure or during the national phase.

**Information in Braille**

54. Is it necessary to state the pharmaceutical form in Braille?

No, this is not a requirement. In certain cases when a product is available in different similar pharmaceutical forms it is however recommended.

EDQM patient friendly terms could be used if they are also used as printed text on the labelling.
Guideline on Nordic packages

General questions concerning the package leaflet

55. Is it possible to have a combined multilingual leaflet if the strengths differ?
Last update: 2018-04-23

DK: It is not acceptable to have a combined PL if the strengths differ. The information in the different PL’s should be “identical”.

FI, NO, SE: A combined PL with more strengths mentioned in the PL than in the PL for the other language could be accepted on a case by case basis if this would be the only way for the other country to get the product on the market.

IS: Can accept a combined PL even if the strengths differ, no matter how they differ.

56. Is it possible to have a combined multilingual leaflet if the package sizes or packages types differ?
Last update: 2018-04-23

Yes. The registered packages types and sizes can be listed for each country in the section 6 of the package leaflet. The storage conditions in section 5 should be the same for the different package types and sizes.

For example:
In Finland:
A LDPE bottle in a carton box 10 x 100 ml, 10 x 250 ml, 10 x 500 ml
A Ecobag plastic bag with a plastic overwrap in a carton box 20 x 50 ml, 20 x 100 ml
In Sweden:
A LDPE bottle in a carton box 10 x 100 ml, 20 x 100 ml, 10 x 250 ml, 10 x 500 ml, 10 x 1000 ml

The situation is relevant for national products when the leaflets are harmonised in everything else except the pack sizes and types.

57. Can the symbol for a trademark (™ and ®) be used in the printed version of package leaflets?
Last update: 2015-02-25

These symbols can be used at the top of the PIL, i.e. where the product name is mentioned the first time in the package leaflet for medicinal products for human and veterinary use.

58. Is it necessary to print the list of names of the product in each member state which participates in a DCP or MRP in the package leaflet?
Last update: 2018-04-23

FI, NO, SE: No, this list does not have to be included.

DK, IS: No, this list of medicinal product names authorised in other EEA countries does not have to be included if required for reasons of space.

However, if the list is part of the nationally approved package leaflet text it has to be included in the printed version too. Please see an example below.
Guideline on Nordic packages

For a Nordic multilingual package when the list of names is included:

In the printed version the list only needs to be printed once, e.g. after the last language in the printed package leaflet. The heading of this section shall however be stated in all relevant languages. The names of the countries can be stated by using the ISO abbreviations for the countries, i.e. the names of the countries must not be stated in the different languages. Note that if the name of the product is the same in two or more countries, this can be stated in one line. Example for a 5 language package leaflet:

“Dette legemidlet er godkjent i EØS-landene med følgende navn:/ Tällä lääkevalmisteella on myyntilupa/rekisteröinti Euroopan talousalueeseen kuuluvissa jäsenvaltioissa seuraavilla kauppanimillä:/ Dette lægemiddel er godkendt i EEAs medlemslande under følgende navne:/ Detta läkemedel är godkänt inom Europeiska ekonomiska samarbetsområdet under namnen:/ Þetta líf hefur markaðsleyfi í löndum Evrópska efnahagsvæðisins undir eftirfarandi heitum:

AT, CZ, DE, DK, EL, FI, IS, NO, PL, SE, SL: <Product name A>.

BE: <Product name B>.

FR: <Product name C>.

IE, UK: <Product name D>.

IT, PT: <Product name E>.”

59. Is it necessary to print the name and address of the manufacturer responsible for batch release in the package leaflet?

Yes, but if the marketing authorisation holder and the manufacturer are the same, i.e. the same company and address, the general heading “Marketing Authorisation Holder and Manufacturer” can be used and this information can be stated only once.

60. In cases where more than one manufacturer responsible for batch release is approved, should all be listed in the word version of the package leaflet?

In cases where more than one manufacturer responsible for batch release is approved, all should be listed in the word version of the package leaflet.

The printed version of the package leaflet must clearly identify the manufacturer responsible for the release of the concerned batch or mention only the specific manufacturer responsible for the release of that batch.
Guideline on Nordic packages

Annex I

Last update: 2018-04-23

The dummy mock-ups in the FAQ document are only examples of Nordic packages and don’t explain details about font sizes etc.

Carton

The below drawing of a five language carton is an example of how a five language carton could be prepared. There should be a clear demarcation between the different languages used; the information provided in each language should be assembled. Avoid excessive use of “/”. 
Guideline on Nordic packages

**Product name xx mg**
active subst.
50 tabl/tofel 1 tabl/tofel: active subst. xx mg, lactose, sacchar.

**Product name xx mg**
active subst.
50 filmomtrukne tabletter/kalvopäällysteistä tablettia/
filmdragerade tabletter/filmhülsösºr tofel

Empty space for the pharmacy label

**Barcode / 2D code**
The Nordic Company, Kongeberg
Danmark/Tanska/Danmark
MNr 123456 (DK), 123456 (FI), 12-1234
(NO), 123456 (SE), IE/1/xx/xx/xx

**EXP. Lat.**

- **DK**: Må ikke opbevares over 25°C.
  Opbevares udløseligt for 12 mån.
  Læs indlægssiden inden brug.
- **FI**: Säilytä alle 25°C.
  El. laukun ulottuvilla oikä näkymälle.
  Lue pakkausoleellis ehtojen käyttöä.
- **NO**: Oppbevares ved høys: 25°C.
  Oppbevares utløselig for barn.
  Les pakningsvedlegget før bruk.
- **SE**: Förvaras vid högst 25°C.
  Förvaras utan syn- och råckhåll för barn.
  Läs bipacksedeln före användning.
- **IE**: Góymá éidí vía hreim híma en 25°C.
  Góymá þar sem bör mærku ná til ná
  sá.
  Lest fylgiseðilins fyrir notuín.

Dim: 117*61*20 mm

**PRODUCT NAME xx mg**

Braille: Product name xx mg
Guideline on Nordic packages

Small label (e.g. vial, ampoule)

Product name xx mg/ml
active subst.
Inj./Stl. 2 ml
Sterile
Lot:
Exp:

Carton for a SE/FI package (the format also applicable for DK/IS/NO), concentrate for solution for injection

Product name xx mg/ml
active subst.
konzentrat till infusionsvätska,
lösning,
infusionskoncentrati, ljuost a varten

Cytostaticum
10 ml = yy mg
Intravenöös användning/
Laskiimoon

Product name xx mg/ml
active subst.
koncentrat till infusionsvätska,
lösning,
infusionskoncentrati, ljuost a varten

Cytostaticum
10 ml = yy mg
Intravenöös användning/
Laskiimoon

Barcode/ 2D code

Label (bottle)

Product name xx mg/ml
active subst.
sterill koncentrat/ steril koncentraatti
Cytostaticum 10 ml = yy mg

Lot:
Exp: